Matches in Wikidata for { <http://www.wikidata.org/entity/Q37702449> ?p ?o ?g. }
- Q37702449 description "article científic" @default.
- Q37702449 description "article scientifique" @default.
- Q37702449 description "articolo scientifico" @default.
- Q37702449 description "artigo científico" @default.
- Q37702449 description "artículu científicu espublizáu en 2017" @default.
- Q37702449 description "bilimsel makale" @default.
- Q37702449 description "scientific article published on 08 March 2017" @default.
- Q37702449 description "vedecký článok" @default.
- Q37702449 description "vetenskaplig artikel" @default.
- Q37702449 description "videnskabelig artikel" @default.
- Q37702449 description "vědecký článek" @default.
- Q37702449 description "wetenschappelijk artikel" @default.
- Q37702449 description "wissenschaftlicher Artikel" @default.
- Q37702449 description "наукова стаття, опублікована в березні 2017" @default.
- Q37702449 description "научни чланак" @default.
- Q37702449 description "գիտական հոդված հրատարակված 2017 թվականի մարտի 8-ին" @default.
- Q37702449 description "مقالة علمية نشرت في 08 مارس 2017" @default.
- Q37702449 name "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 name "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 name "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 type Item @default.
- Q37702449 label "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 label "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 label "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 prefLabel "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 prefLabel "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 prefLabel "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 P1433 Q37702449-51977969-766A-4DBF-A506-2ECFFE84B573 @default.
- Q37702449 P1476 Q37702449-CA757AC6-EEA5-40C2-924D-08CA1497EE22 @default.
- Q37702449 P2093 Q37702449-2AF1C88A-4D02-4AA8-9968-85F38D651B0B @default.
- Q37702449 P2093 Q37702449-43AF4F29-CC16-471A-AFAF-DE76B89F1216 @default.
- Q37702449 P2093 Q37702449-B2857F84-E4EB-4B88-A7AC-F784D265808A @default.
- Q37702449 P2093 Q37702449-CDF61E5B-D2DC-4C31-9454-E9FEFC52C59B @default.
- Q37702449 P2093 Q37702449-D0FD0AB1-3A52-447A-9EDD-FEEEEEA158E0 @default.
- Q37702449 P2093 Q37702449-FEF20CB0-8D41-4BC6-A402-92EB3CC7C82C @default.
- Q37702449 P275 Q37702449-7bb582aa-58aa-4825-9fa2-7047d08c2851 @default.
- Q37702449 P2860 Q37702449-1CF6FDDC-498E-4F66-A080-FD52B7FB1829 @default.
- Q37702449 P2860 Q37702449-1DBD0D3C-A1A4-4E5D-8D01-E066DB878C5A @default.
- Q37702449 P2860 Q37702449-26C048AF-376A-43A1-9517-B8B59F02B78A @default.
- Q37702449 P2860 Q37702449-30A748B3-98F3-47E5-B44B-D27B3077D599 @default.
- Q37702449 P2860 Q37702449-394D96C4-1392-4C34-AFFA-4487FB34C8A0 @default.
- Q37702449 P2860 Q37702449-3E311164-9859-4DC9-BF28-F76D83B1AB89 @default.
- Q37702449 P2860 Q37702449-3ECF84CE-78B1-45C7-BA42-D7F13D91CEB2 @default.
- Q37702449 P2860 Q37702449-418D4D14-9F73-419A-ADDB-878BAEFC48C5 @default.
- Q37702449 P2860 Q37702449-4799038F-7CC9-4732-A35F-384C63F7B964 @default.
- Q37702449 P2860 Q37702449-4B58B3DD-E235-428C-B5A0-8D256C78CB80 @default.
- Q37702449 P2860 Q37702449-4EB06F62-48FB-4452-B937-425A146F6215 @default.
- Q37702449 P2860 Q37702449-502C73FA-535E-4E6C-ADA4-1E4656A4640C @default.
- Q37702449 P2860 Q37702449-510BABF9-2451-4673-B383-63347A3949DB @default.
- Q37702449 P2860 Q37702449-57B61645-AD62-4DFD-B0C3-1E9DBFEEF8D1 @default.
- Q37702449 P2860 Q37702449-5D96F76F-30B5-4375-B2A4-97D671FF1C8F @default.
- Q37702449 P2860 Q37702449-6819C2F5-ACF0-4B22-991A-FC25558601CB @default.
- Q37702449 P2860 Q37702449-6AE528CD-3607-4134-9992-CDFAFA6E1248 @default.
- Q37702449 P2860 Q37702449-8BD6343C-FCEB-4831-8C56-13B32098DAE8 @default.
- Q37702449 P2860 Q37702449-93DC4607-7584-4788-BB0C-7F2B71C8CDC1 @default.
- Q37702449 P2860 Q37702449-9ACFE27D-B0CB-49BF-9E5C-0B6E8560EB83 @default.
- Q37702449 P2860 Q37702449-9C22EE8C-1426-4119-B01B-2FC5E326CDBB @default.
- Q37702449 P2860 Q37702449-A158257F-C788-4CB0-80ED-6D6CACED5671 @default.
- Q37702449 P2860 Q37702449-B5DA3262-EA98-4DA4-9301-1BF2ADEBFEE5 @default.
- Q37702449 P2860 Q37702449-C33CEB4E-BE6A-43B3-90C4-9E25ED3AE932 @default.
- Q37702449 P2860 Q37702449-C784B15D-C56C-4AE9-B2F3-7A716EEC28CA @default.
- Q37702449 P2860 Q37702449-C8564406-1FB6-4EDA-924D-DEAD34DACDC0 @default.
- Q37702449 P2860 Q37702449-C9A71940-AFDF-47E4-AB10-6BE36D804E4A @default.
- Q37702449 P2860 Q37702449-CB47659C-2D56-4C92-843D-B3141C50EC56 @default.
- Q37702449 P2860 Q37702449-D342C7C2-70AF-4FA3-A3E3-805EF821773A @default.
- Q37702449 P2860 Q37702449-E1D49BBC-37A7-436A-BACF-A603A53B94B9 @default.
- Q37702449 P2860 Q37702449-EB00A273-70A7-4072-B98D-760C65B9C33A @default.
- Q37702449 P2860 Q37702449-EC096587-DE81-437E-83D0-054BF2150348 @default.
- Q37702449 P2860 Q37702449-FD74C66C-5F05-465F-966F-8C882835A566 @default.
- Q37702449 P304 Q37702449-AED9DE3D-5F7C-4B35-AAAE-255B13585DD4 @default.
- Q37702449 P31 Q37702449-39DF18B7-C52F-498D-A2EA-25C015434601 @default.
- Q37702449 P356 Q37702449-23599002-3BE8-4998-8EAC-F06126EBF97F @default.
- Q37702449 P407 Q37702449-3DBF9A94-5F43-45A3-9B37-9496D5BDAD0C @default.
- Q37702449 P478 Q37702449-B50A7FAB-E8E0-4B8A-BD85-75A4758D83CB @default.
- Q37702449 P577 Q37702449-FA8C1955-A0AD-42AB-8EB4-9F1655325709 @default.
- Q37702449 P6216 Q37702449-77f37d04-1981-4d2e-88ac-dbaebb990e2f @default.
- Q37702449 P698 Q37702449-4BA4C05F-56B2-4D83-B9FC-B7AAA01E432B @default.
- Q37702449 P921 Q37702449-B4E7B225-836B-4C2A-8BB6-43BAA6B44C2F @default.
- Q37702449 P921 Q37702449-FE9ACD95-BEC5-4F94-9A55-00256E3262DC @default.
- Q37702449 P932 Q37702449-144234B5-CB0C-46EA-9A9B-000447FDEADD @default.
- Q37702449 P356 IJN.S131235 @default.
- Q37702449 P698 28331310 @default.
- Q37702449 P1433 Q6051502 @default.
- Q37702449 P1476 "Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment" @default.
- Q37702449 P2093 "Bo Wu" @default.
- Q37702449 P2093 "Hai-Bo Xu" @default.
- Q37702449 P2093 "Liu-Jie Zhang" @default.
- Q37702449 P2093 "Ren-Xi Zhuo" @default.
- Q37702449 P2093 "Shi-Wen Huang" @default.
- Q37702449 P2093 "Shu-Ting Lu" @default.
- Q37702449 P275 Q18810331 @default.
- Q37702449 P2860 Q28542871 @default.
- Q37702449 P2860 Q33708231 @default.
- Q37702449 P2860 Q34588261 @default.
- Q37702449 P2860 Q34604376 @default.
- Q37702449 P2860 Q35032561 @default.
- Q37702449 P2860 Q35158861 @default.
- Q37702449 P2860 Q35585791 @default.
- Q37702449 P2860 Q35771214 @default.
- Q37702449 P2860 Q36431063 @default.